Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 23%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is positioned for strong growth, underscored by its robust cash position of approximately €16.7 billion, which provides significant financial flexibility to support ongoing and future development initiatives. The company's diversified oncology pipeline, including promising candidates like pumitamig and the adjusted ROSETTA-LUNG-02 study, highlights its commitment to advancing innovative therapies, bolstering the potential for meaningful upside in 2026. Additionally, anticipated positive interim Phase 3 data for its gotistobart treatment in squamous NSCLC further solidifies BioNTech's prospects, especially as it pivots towards becoming a fully integrated oncology company.

Bears say

The financial outlook for BioNTech is negatively impacted by a projected decline in COVID vaccine revenues, anticipating a 24% decrease in FY26, which raises concerns about the company's cash flow to support its research and development initiatives in oncology. Additionally, challenges such as lower than expected manufacturing capacity for personalized therapeutics and potential delays in advancing oncology programs could hinder revenue generation and materially affect future financial forecasts. Furthermore, the company faces significant risks, including negative clinical data, slow market uptake, and various regulatory and commercial uncertainties, all of which contribute to an overall pessimistic view of its financial trajectory.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.